"rationale","instanceType","description","id","label","name","uuid:ID"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign","The main design for the study","StudyDesign_1","","Study Design 1","1014aec4-ba7f-4499-8344-446018502186"
